Lung Cancer

© Getty Images

Genprex bags FDA orphan drug designation for lung cancer therapy

By Isabel Cameron

Genprex has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead candidate, Reqorsa immunogene therapy (quaratusugene ozeplasmid), for the treatment of small cell lung cancer (SCLC).

© GettyImages/Mohammed Haneefa Nizamudeen

Setback for Novartis drug in advanced lung cancer trial

By Jane Byrne

Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer compared to just chemotherapy...